Evidence map›Paper›PMID 25732044›Full record

ArticleClinical pharmacology and therapeutics2015

Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria.

N C Sambol, L Yan, D J Creek, S A McCormack, E Arinaitwe, V Bigira, H Wanzira, A Kakuru, J W Tappero, N Lindegardh and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Article
  9. Article
  10. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 5 countries.

N C SambolDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
L YanDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
D J CreekDepartment of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA.
S A McCormackDepartment of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA.
E ArinaitweMakerere University School of Medicine, Kampala, Uganda.
V BigiraMakerere University School of Medicine, Kampala, Uganda.
H WanziraMakerere University School of Medicine, Kampala, Uganda.
A KakuruMakerere University School of Medicine, Kampala, Uganda.
J W TapperoCenters for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
N LindegardhMahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
J TarningMahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
F NostenCentre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
F T AweekaDepartment of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA.
S ParikhYale School of Public Health and Medicine, New Haven, Connecticut, USA.
University of California, San Francisco · USMakerere University · UGNuffield Orthopaedic Centre · GBCenters for Disease Control and Prevention · USMahidol University · TH

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
Optimizing HIV-malaria treatment in a shifting treatment and resistance landscape in AfricaR01HD068174 · NICHD · YALE UNIVERSITY · PI FRANCESCA T. AWEEKA, SUNIL PARIKH · 2011 to 2026
$8.1M
Intramural CDC HHS CC999999NIAID NIH HHS P30 AI027763NICHD NIH HHS R01 HD068174Wellcome Trust
6 · The paper itself

Abstract

This prospective trial investigated the population pharmacokinetics of piperaquine given with dihydroartemisinin to treat uncomplicated malaria in 107 Ugandan children 6 months to 2 years old, an age group previously unstudied. Current weight-based dosing does not adequately address physiological changes in early childhood. Patients were administered standard 3-day oral doses and provided 1,282 capillary plasma concentrations from 218 malaria episodes. Less than 30% of treatments achieved 57 ng/mL on day 7. A three-compartment model with first-order absorption described the data well. Age had a statistically significant effect (P < 0.005) on clearance/bioavailability in a model that accounts for allometric scaling. Simulations demonstrated that higher doses in all children, but especially in those with lower weight for age, are required for adequate piperaquine exposure, although safety and tolerance will need to be established. These findings support other evidence that both weight- and age-specific guidelines for piperaquine dosing in children are urgently needed.

Indexed as

AntimalarialsArtemisininsChild, PreschoolDrug Therapy, CombinationHumansInfantMalariaPiperazinesProspective StudiesQuinolinesUgandaAntimalarialsArtemisininsartenimolpiperaquinePiperazinesQuinolines

Identifiers

PMID25732044
PMCPMC5088713
OpenAlexW2026779157

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.